Journal
CANCER LETTERS
Volume 343, Issue 1, Pages 33-41Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2013.09.011
Keywords
Breast cancer; Metabonomics; Metabolomics; NMR; Serum; Metastatic
Categories
Funding
- French National Cancer Institute (INCa)
Ask authors/readers for more resources
Breast cancer (BC) displays a high heterogeneity from histology to prognosis, metastatic evolution and treatment responses. We report here a H-1 NMR-based metabolic phenotyping study aiming at identifying coordinated metabolic serum changes associated with advanced metastatic breast cancer (MBC) in comparison to the localized early disease (EBC). A model discriminating EBC and MBC patients is obtained (n = 85: 46 EBC and 39 MBC), and validated with an independent cohort (n = 112: 61 EBC and 51 MBC; 89.8% sensitivity, 79.3% specificity). We identify 9 statistically significant metabolites involved in this discrimination: histidine, acetoacetate, glycerol, pyruvate, glycoproteins (N-acetyl), mannose, glutamate and phenylalanine. This work illustrates the strong potential of NMR metabolic phenotyping for the diagnosis, prognosis, and management of cancer patients. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available